Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| INM | 8-K | bullish | 8/10 | InMed Pharmaceuticals (INM) entered into a definitive agreement to acquire Mentari Therapeutics via reverse merger, with | May 19, 2026 |
| EDSA | PRESS-RELEASE | bullish | 6/10 | Edesa Biotech announced an oral presentation of Phase 3 data for paridiprubart in acute kidney injury at the ERA Congres | May 19, 2026 |
| TOMZ | 8-K | bearish | 6/10 | TOMI Environmental Solutions reports the unexpected death of CFO David Vanston on May 11, 2026 and appoints Niroshan Sri | May 19, 2026 |
| LPCN | 8-K | neutral | 4/10 | Lipocine announced that its Phase 3 clinical data for LPCN 1154 (oral brexanolone for postpartum depression) has been ac | May 19, 2026 |
| RGC | 6-K | bullish | 5/10 | Regencell Bioscience Holdings priced a registered direct offering of 985,222 ordinary shares at $20.30 per share, raisin | May 19, 2026 |
| OPTHF | F-1/A | neutral | 5/10 | Optimi Health Corp., a Canadian GMP-compliant psychedelic pharmaceutical manufacturer, filed Amendment No. 8 (F-1/A) to | May 19, 2026 |
| PPCB | PRESS-RELEASE | neutral | 6/10 | Propanc Biopharma engaged a European CDMO for GMP manufacturing of its lead asset PRP, a proenzyme therapy for solid tum | May 19, 2026 |
| OGEN | 8-K | neutral | 4/10 | Oragenics filed an 8-K with a shareholder update and investor presentation ahead of the Sidoti Micro-Cap Conference. The | May 19, 2026 |
| RNXT | PRESS-RELEASE | neutral | 3/10 | RenovoRx announced management participation in an AGP healthcare showcase and highlighted record Q1 2026 RenovoCath reve | May 19, 2026 |
| TTRX | 8-K | neutral | 2/10 | Turn Therapeutics (TTRX) announced that CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference 20 | May 19, 2026 |
| ARTV | 8-K | neutral | 3/10 | Artiva Biotherapeutics announced a reorganization of its executive team: CFO Thad Huston is departing effective May 22, | May 19, 2026 |
| AIM | 8-K | mixed | 6/10 | AIM ImmunoTech filed an 8-K reporting a $1.68M debt extension with Streeterville Capital to June 2027, a turnaround from | May 19, 2026 |
| ONCO | PRESS-RELEASE | bearish | 5/10 | Onconetix announces a 1-for-10 reverse stock split effective May 21, 2026, to regain compliance with Nasdaq's $1 minimum | May 19, 2026 |
| ARTV | PRESS-RELEASE | neutral | 4/10 | Artiva Biotherapeutics appointed Diego Miralles, M.D., as President and Head of R&D. Dr. Miralles brings >20 years of dr | May 19, 2026 |
| PSTV | PRESS-RELEASE | neutral | 4/10 | Plus Therapeutics announced a strategic partnership with Ephemeral Technologies, an AI firm founded by former Palantir h | May 19, 2026 |
| BLRX | 6-K | bullish | 5/10 | BioLineRx announced new preclinical GLIX1 data showing potent anti-tumor activity in glioblastoma (GBM) models, includin | May 19, 2026 |
| ZBIO | PRESS-RELEASE | bullish | 7/10 | Zenas BioPharma announced that the Phase 3 INDIGO trial of obexelimab in IgG4-Related Disease met its primary endpoint a | May 19, 2026 |
| CGEM | PRESS-RELEASE | bullish | 5/10 | Cullinan Therapeutics announced that the FDA granted Orphan Drug Designation (ODD) to its CLN-049, a FLT3xCD3 T cell eng | May 19, 2026 |
| IMUX | 8-K | neutral | 3/10 | Immunic appointed Michael W. Bonney as Chair of the Board, effective May 16, 2026. Bonney brings extensive biopharmaceut | May 19, 2026 |
| XRTX | 6-K, PRESS-RELEASE | bearish | 6/10 | XORTX closed a $5M public offering of 2.66M common shares/pre-funded warrants at $1.88/share, representing massive dilut | May 19, 2026 |
| OKYO | 6-K | neutral | 3/10 | OKYO Pharma announced the appointment of Dr. Marta Sacchetti to its Scientific Advisory Board. Dr. Sacchetti's expertise | May 19, 2026 |
| KRRO | 8-K | bullish | 6/10 | Korro Bio selected KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), a genetic disease affe | May 19, 2026 |
| HROW | CLUSTER | bullish | 7/10 | Harrow CEO Mark Baum, CFO Andrew Boll, and two directors collectively purchased $438K of stock in a 7-day cluster follow | May 19, 2026 |
| TLSA | 6-K | bullish | 5/10 | Tiziana Life Sciences announced updated positive clinical data from its Expanded Access Program for intranasal foralumab | May 19, 2026 |
| CMND | 6-K | bearish | 6/10 | Clearmind Medicine entered into a conversion agreement for $600,000 of convertible notes at $0.30 per share, which is si | May 19, 2026 |
| CMND | 6-K | neutral | 4/10 | Clearmind Medicine announced a 1-for-10 reverse share split effective May 21, 2026, intended to regain compliance with N | May 19, 2026 |
| NAII | PRESS-RELEASE | bearish | 6/10 | NAII reported Q3 FY2026 net sales of $35.5M (+23% YoY) but net loss widened to -$4.3M (-$0.72 EPS) from -$2.2M (-$0.37 E | May 19, 2026 |
| MAIA | DEFA14A | neutral | 2/10 | MAIA filed a DEFA14A amending its proxy statement to disclose related-party compensation paid to Radu Vitoc, brother of | May 19, 2026 |
| TKPHF | 6-K | bearish | 8/10 | A U.S. federal jury returned a verdict against Takeda in the AMITIZA (lubiprostone) antitrust litigation, awarding plain | May 19, 2026 |
| INM | 8-K | bearish | 7/10 | InMed Pharmaceuticals amended preferred investment options held by Armistice Capital, reducing the exercise price from $ | May 19, 2026 |